Pub Date : 2025-12-04DOI: 10.1097/aog.0000000000006135
Ann Oluloro,Mindy Pike,Tiffany Luu,Adrienne Moore,Soledad Jorge,Kemi M Doll
OBJECTIVETo characterize the presenting comorbidity profile of patients with uterine cancer by race and ethnicity and use real-world data to quantify expected effects of common comorbidity eligibility criteria on uterine cancer trial accrual.METHODSThis observational, cross-sectional study used the Vizient Clinical Data Base to identify individuals aged 18 years or older with a uterine cancer diagnosis from 2002 to 2021. Demographic variables and comorbidity diagnoses were identified by International Classification of Diseases, Ninth and Tenth Revision codes and used to construct Charlson, Elixhauser, and National Cancer Institute comorbidity indices. Summary theoretical ineligibility rates were calculated by race based on a modified set of comorbidity-eligibility criteria. Ineligibility rates were compared between groups and differences assessed with logistic regression.RESULTSWe identified 384,093 patients with uterine cancer; 70.0% of the patients were non-Hispanic White, 13.4% were non-Hispanic Black, 7.1% were of unknown race, and 2.8% were non-Hispanic Asian. Across all comorbidity indices, non-Hispanic Black individuals persistently had the highest scores among all racial groups. Comorbidity prevalence varied significantly by race. Non-Hispanic Black individuals had the highest rates of renal failure (11.6%), diabetes (23.4%), and hypertension (49.8%) compared with non-Hispanic White and non-Hispanic Asian individuals. In modeling analyses, non-Hispanic Black individuals had twofold higher odds of trial exclusion based on comorbidities than non-Hispanic White individuals (adjusted odds ratio [aOR] 2.06; 95% CI, 2.02-2.10). Those of unknown race had slightly higher odds (aOR 1.02; 95% CI, 0.99-1.05) and non-Hispanic Asians slightly lower odds (aOR 0.98; 95% CI, 0.94-1.02) of being ineligible relative to non-Hispanic White individuals.CONCLUSIONFor patients with uterine cancer, comorbidity prevalence and comorbidity index scores varied by race. This results in differences in trial eligibility at baseline before any patient engagement. Quantifying the distribution of comorbidities is critical because it allows us to statistically anticipate how individual comorbidity eligibility criteria may hamper the accrual of patients from minoritized groups. This, in turn, can support equity efforts to plan trial eligibility criteria and targeted recruitment.
{"title":"Association Between Comorbidity and Clinical Trial Enrollment for Patients With Uterine Cancer.","authors":"Ann Oluloro,Mindy Pike,Tiffany Luu,Adrienne Moore,Soledad Jorge,Kemi M Doll","doi":"10.1097/aog.0000000000006135","DOIUrl":"https://doi.org/10.1097/aog.0000000000006135","url":null,"abstract":"OBJECTIVETo characterize the presenting comorbidity profile of patients with uterine cancer by race and ethnicity and use real-world data to quantify expected effects of common comorbidity eligibility criteria on uterine cancer trial accrual.METHODSThis observational, cross-sectional study used the Vizient Clinical Data Base to identify individuals aged 18 years or older with a uterine cancer diagnosis from 2002 to 2021. Demographic variables and comorbidity diagnoses were identified by International Classification of Diseases, Ninth and Tenth Revision codes and used to construct Charlson, Elixhauser, and National Cancer Institute comorbidity indices. Summary theoretical ineligibility rates were calculated by race based on a modified set of comorbidity-eligibility criteria. Ineligibility rates were compared between groups and differences assessed with logistic regression.RESULTSWe identified 384,093 patients with uterine cancer; 70.0% of the patients were non-Hispanic White, 13.4% were non-Hispanic Black, 7.1% were of unknown race, and 2.8% were non-Hispanic Asian. Across all comorbidity indices, non-Hispanic Black individuals persistently had the highest scores among all racial groups. Comorbidity prevalence varied significantly by race. Non-Hispanic Black individuals had the highest rates of renal failure (11.6%), diabetes (23.4%), and hypertension (49.8%) compared with non-Hispanic White and non-Hispanic Asian individuals. In modeling analyses, non-Hispanic Black individuals had twofold higher odds of trial exclusion based on comorbidities than non-Hispanic White individuals (adjusted odds ratio [aOR] 2.06; 95% CI, 2.02-2.10). Those of unknown race had slightly higher odds (aOR 1.02; 95% CI, 0.99-1.05) and non-Hispanic Asians slightly lower odds (aOR 0.98; 95% CI, 0.94-1.02) of being ineligible relative to non-Hispanic White individuals.CONCLUSIONFor patients with uterine cancer, comorbidity prevalence and comorbidity index scores varied by race. This results in differences in trial eligibility at baseline before any patient engagement. Quantifying the distribution of comorbidities is critical because it allows us to statistically anticipate how individual comorbidity eligibility criteria may hamper the accrual of patients from minoritized groups. This, in turn, can support equity efforts to plan trial eligibility criteria and targeted recruitment.","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"129 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145674132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1097/aog.0000000000006140
Chidimma Azubuike,Amy Deng,Amie Goodin
Clinical guidelines recommend avoiding cannabinoids, including cannabidiol (CBD), during pregnancy and lactation. Use of CBD is widespread, but prevalence in pregnancy and among women of reproductive age is not well documented. We conducted a cross-sectional analysis using data from the 2022 and 2023 National Survey on Drug Use and Health, with incorporation of survey sampling weights to estimate the prevalence of CBD use. Similar proportions of pregnant women and reproductive-aged women reported ever using CBD in 2022 (353.4 vs 365.1, respectively) and in 2023 (323.4 [95% CI, 259.2-387.6] vs 361.3 [95% CI, 353.6-367.0], respectively) per 1,000 population. More reproductive-aged women had used CBD within the past 30 days compared with pregnant women in 2022 (121.3 vs 43.9, respectively) and in 2023 (113.2 [95% CI, 107.4-118.9] vs 39.3 [95% CI, 16.2-62.4], respectively) per 1,000 population. Due to unknown effects of CBD during pregnancy and prevalent use, clinicians should screen for CBD use to facilitate counseling patients against use in pregnancy and while breastfeeding.
临床指南建议在怀孕和哺乳期避免使用大麻素，包括大麻二酚（CBD）。CBD的使用很普遍，但在怀孕和育龄妇女中的流行情况没有很好的记录。我们使用2022年和2023年全国药物使用和健康调查的数据进行了横断面分析，并结合调查抽样权重来估计CBD使用的流行程度。在2022年（353.4 vs 365.1）和2023年（323.4 [95% CI, 259.2-387.6] vs 361.3 [95% CI, 353.6-367.0]）每1000人报告使用过CBD的孕妇和育龄妇女比例相似。与2022年（121.3比43.9）和2023年（113.2 [95% CI, 107.4-118.9]比39.3 [95% CI, 16.2-62.4]）的孕妇相比，在过去30天内使用过CBD的育龄妇女更多。由于CBD在怀孕期间的未知影响和普遍使用，临床医生应该筛查CBD的使用，以方便咨询患者在怀孕和哺乳期间不要使用CBD。
{"title":"Nationwide Prevalence of Cannabidiol Use in Pregnancy and in Women of Reproductive Age.","authors":"Chidimma Azubuike,Amy Deng,Amie Goodin","doi":"10.1097/aog.0000000000006140","DOIUrl":"https://doi.org/10.1097/aog.0000000000006140","url":null,"abstract":"Clinical guidelines recommend avoiding cannabinoids, including cannabidiol (CBD), during pregnancy and lactation. Use of CBD is widespread, but prevalence in pregnancy and among women of reproductive age is not well documented. We conducted a cross-sectional analysis using data from the 2022 and 2023 National Survey on Drug Use and Health, with incorporation of survey sampling weights to estimate the prevalence of CBD use. Similar proportions of pregnant women and reproductive-aged women reported ever using CBD in 2022 (353.4 vs 365.1, respectively) and in 2023 (323.4 [95% CI, 259.2-387.6] vs 361.3 [95% CI, 353.6-367.0], respectively) per 1,000 population. More reproductive-aged women had used CBD within the past 30 days compared with pregnant women in 2022 (121.3 vs 43.9, respectively) and in 2023 (113.2 [95% CI, 107.4-118.9] vs 39.3 [95% CI, 16.2-62.4], respectively) per 1,000 population. Due to unknown effects of CBD during pregnancy and prevalent use, clinicians should screen for CBD use to facilitate counseling patients against use in pregnancy and while breastfeeding.","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"1 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145673826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1097/AOG.0000000000006096
Dehlia Moussaoui, Michele A O'Connell, Charlotte V Elder, Sonia R Grover, Ken C Pang
{"title":"Characteristics of Menstrual Suppression and Its Association With Mental Health in Transgender Adolescents: Correction.","authors":"Dehlia Moussaoui, Michele A O'Connell, Charlotte V Elder, Sonia R Grover, Ken C Pang","doi":"10.1097/AOG.0000000000006096","DOIUrl":"10.1097/AOG.0000000000006096","url":null,"abstract":"","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"146 6","pages":"925-927"},"PeriodicalIF":4.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145655067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-30DOI: 10.1097/AOG.0000000000006106
Ann M Bruno, Amanda A Allshouse, Torri D Metz
<p><strong>Objective: </strong>To evaluate the association between maximum oxytocin dose and uterine rupture among individuals undertaking a trial of labor after cesarean (TOLAC). Secondarily, to evaluate the association between total time on oxytocin and time at maximum oxytocin dose and uterine rupture.</p><p><strong>Methods: </strong>We conducted a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Assessment of Perinatal Excellence study, an observational cohort of deliveries after 23 weeks of gestation across 25 U.S. hospitals from 2008 to 2011. Individuals with a singleton, cephalic, live fetus who had one prior cesarean delivery and were undertaking TOLAC, including those undergoing spontaneous, augmented, or induced labor, were included. Those with a contraindication to TOLAC or a fetus with an anomaly or known genetic abnormality were excluded. The exposure was intrapartum oxytocin dose in milli-international units per minute (milli-international units/min), assessed both categorically (0, 1-20, more than 20 milli-international units/min) and continuously. The primary outcome was uterine rupture. Secondary outcomes were vaginal birth after cesarean (VBAC), blood transfusion, and intensive care unit (ICU) admission. Trends in outcomes by oxytocin were assessed using the Cochran-Armitage trend test. Multivariable modeling estimated the association between maximum oxytocin dose (both as a categorical and continuous variable) and outcomes. The duration of any oxytocin, the duration at the maximum dose of oxytocin, and outcomes were assessed.</p><p><strong>Results: </strong>Of 5,201 individuals undergoing TOLAC, 3,406 (65.5%) received 0 milli-international units/min of oxytocin, 1,659 (31.9%) received 1-20 milli-international units/min, and 136 (2.6%) received more than 20 milli-international units/min. The majority of the cohort (n=3,391) entered spontaneous labor; 1,076 patients received augmentation and 733 were induced. The range of maximum oxytocin doses was 0-60 milli-international units/min. There were 37 cases of uterine rupture (0.7%, 95% CI, 0.5-0.9%). The frequency of uterine rupture by maximum oxytocin dose category was 0.2% (n=7) with no oxytocin (0 milli-international units/min), 1.6% (n=27) with an oxytocin dose of 1-20 milli-international units/min, and 2.2% (n=3) with oxytocin doses greater than 20 milli-international units/min. Higher maximum oxytocin doses were associated with a trend of an increase in uterine rupture (P<.001 Cochran-Armitage test of trend). In adjusted modeling, maximum oxytocin doses of 1-20 milli-international units/min and doses greater than 20 milli-international units/min were associated with uterine rupture (adjusted odds ratio [aOR] 8.82, 95% CI, 3.61-21.6; and aOR 11.0, 95% CI, 2.67-45.3, respectively), compared with 0 milli-international units/min; however, a higher maximum dose (more than 20 milli-interna
{"title":"Maximum Oxytocin Dose and Uterine Rupture During Trial of Labor After Cesarean.","authors":"Ann M Bruno, Amanda A Allshouse, Torri D Metz","doi":"10.1097/AOG.0000000000006106","DOIUrl":"10.1097/AOG.0000000000006106","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between maximum oxytocin dose and uterine rupture among individuals undertaking a trial of labor after cesarean (TOLAC). Secondarily, to evaluate the association between total time on oxytocin and time at maximum oxytocin dose and uterine rupture.</p><p><strong>Methods: </strong>We conducted a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Assessment of Perinatal Excellence study, an observational cohort of deliveries after 23 weeks of gestation across 25 U.S. hospitals from 2008 to 2011. Individuals with a singleton, cephalic, live fetus who had one prior cesarean delivery and were undertaking TOLAC, including those undergoing spontaneous, augmented, or induced labor, were included. Those with a contraindication to TOLAC or a fetus with an anomaly or known genetic abnormality were excluded. The exposure was intrapartum oxytocin dose in milli-international units per minute (milli-international units/min), assessed both categorically (0, 1-20, more than 20 milli-international units/min) and continuously. The primary outcome was uterine rupture. Secondary outcomes were vaginal birth after cesarean (VBAC), blood transfusion, and intensive care unit (ICU) admission. Trends in outcomes by oxytocin were assessed using the Cochran-Armitage trend test. Multivariable modeling estimated the association between maximum oxytocin dose (both as a categorical and continuous variable) and outcomes. The duration of any oxytocin, the duration at the maximum dose of oxytocin, and outcomes were assessed.</p><p><strong>Results: </strong>Of 5,201 individuals undergoing TOLAC, 3,406 (65.5%) received 0 milli-international units/min of oxytocin, 1,659 (31.9%) received 1-20 milli-international units/min, and 136 (2.6%) received more than 20 milli-international units/min. The majority of the cohort (n=3,391) entered spontaneous labor; 1,076 patients received augmentation and 733 were induced. The range of maximum oxytocin doses was 0-60 milli-international units/min. There were 37 cases of uterine rupture (0.7%, 95% CI, 0.5-0.9%). The frequency of uterine rupture by maximum oxytocin dose category was 0.2% (n=7) with no oxytocin (0 milli-international units/min), 1.6% (n=27) with an oxytocin dose of 1-20 milli-international units/min, and 2.2% (n=3) with oxytocin doses greater than 20 milli-international units/min. Higher maximum oxytocin doses were associated with a trend of an increase in uterine rupture (P<.001 Cochran-Armitage test of trend). In adjusted modeling, maximum oxytocin doses of 1-20 milli-international units/min and doses greater than 20 milli-international units/min were associated with uterine rupture (adjusted odds ratio [aOR] 8.82, 95% CI, 3.61-21.6; and aOR 11.0, 95% CI, 2.67-45.3, respectively), compared with 0 milli-international units/min; however, a higher maximum dose (more than 20 milli-interna","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"146 6","pages":"843-850"},"PeriodicalIF":4.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12948276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145654977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1097/AOG.0000000000006097
Patrick Kim, David J Rivera Vazquez, Tiffany Lowtan, Kelsey Pozerski, Bradley H Sipe, Rachelle Schwartz
{"title":"Notice of Retraction: \"Does an Early Isolated Increase in Fetal Abdominal Circumference Heighten the Risk of Macrosomia? [ID 1242]\" and Notice of Retraction: \"Does an Early Isolated Decrease in Fetal Abdominal Circumference Heighten the Risk of Growth Restriction? [ID 1300]\".","authors":"Patrick Kim, David J Rivera Vazquez, Tiffany Lowtan, Kelsey Pozerski, Bradley H Sipe, Rachelle Schwartz","doi":"10.1097/AOG.0000000000006097","DOIUrl":"https://doi.org/10.1097/AOG.0000000000006097","url":null,"abstract":"","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"146 6","pages":"928"},"PeriodicalIF":4.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145655030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1097/AOG.0000000000006111
{"title":"PUBLICATIONS: December 2025.","authors":"","doi":"10.1097/AOG.0000000000006111","DOIUrl":"https://doi.org/10.1097/AOG.0000000000006111","url":null,"abstract":"","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"146 6","pages":"929"},"PeriodicalIF":4.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-08-28DOI: 10.1097/AOG.0000000000006042
Amy Pearson, Katerina Shvartsman, Wu Zeng, Jill Brown
Objective: To evaluate the cost effectiveness of salpingectomy compared with vasectomy for couples seeking permanent contraception.
Methods: We developed a decision tree model that used TreeAge to evaluate the cost effectiveness of vasectomy compared with salpingectomy for a hypothetical cohort of 800,000 people, the number of male and female patients who undergo permanent contraception procedures in the United States annually. Effectiveness was expressed in quality-adjusted life-years (QALYs), and the willingness-to-pay (WTP) threshold was set to $100,000 per QALY gained or lost. We derived costs, probabilities, and utilities from the literature, and estimated the incremental cost-effectiveness ratio (ICER) between the two strategies. We completed a probabilistic sensitivity analysis with 10,000 simulations and created a cost-effectiveness acceptability curve for WTP thresholds from $0 to $200,000. Secondary outcomes included the number of unintended pregnancies, ovarian cancer cases, and ovarian cancer deaths.
Results: Salpingectomy was not a cost-effective strategy, with an ICER of $143,769 per QALY gained compared with vasectomy. Probabilistic sensitivity analysis showed that the chance of vasectomy being cost effective was 81.5% but decreased to 14.7% with a WTP threshold of $200,000. Annually, salpingectomy was associated with 1,215 fewer unintended pregnancies, 6,085 fewer ovarian cancer cases, and 4,921 fewer ovarian cancer deaths compared with vasectomy.
Conclusion: Salpingectomy is not cost effective compared with vasectomy at a WTP threshold of $100,000, despite lower unintended pregnancy rates and societal ovarian cancer burden. Shared decision making, including a discussion of the long-term health benefits of salpingectomy, is important for couples deciding on permanent contraception procedures.
{"title":"Cost Effectiveness of Salpingectomy Compared With Vasectomy for Permanent Contraception.","authors":"Amy Pearson, Katerina Shvartsman, Wu Zeng, Jill Brown","doi":"10.1097/AOG.0000000000006042","DOIUrl":"10.1097/AOG.0000000000006042","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the cost effectiveness of salpingectomy compared with vasectomy for couples seeking permanent contraception.</p><p><strong>Methods: </strong>We developed a decision tree model that used TreeAge to evaluate the cost effectiveness of vasectomy compared with salpingectomy for a hypothetical cohort of 800,000 people, the number of male and female patients who undergo permanent contraception procedures in the United States annually. Effectiveness was expressed in quality-adjusted life-years (QALYs), and the willingness-to-pay (WTP) threshold was set to $100,000 per QALY gained or lost. We derived costs, probabilities, and utilities from the literature, and estimated the incremental cost-effectiveness ratio (ICER) between the two strategies. We completed a probabilistic sensitivity analysis with 10,000 simulations and created a cost-effectiveness acceptability curve for WTP thresholds from $0 to $200,000. Secondary outcomes included the number of unintended pregnancies, ovarian cancer cases, and ovarian cancer deaths.</p><p><strong>Results: </strong>Salpingectomy was not a cost-effective strategy, with an ICER of $143,769 per QALY gained compared with vasectomy. Probabilistic sensitivity analysis showed that the chance of vasectomy being cost effective was 81.5% but decreased to 14.7% with a WTP threshold of $200,000. Annually, salpingectomy was associated with 1,215 fewer unintended pregnancies, 6,085 fewer ovarian cancer cases, and 4,921 fewer ovarian cancer deaths compared with vasectomy.</p><p><strong>Conclusion: </strong>Salpingectomy is not cost effective compared with vasectomy at a WTP threshold of $100,000, despite lower unintended pregnancy rates and societal ovarian cancer burden. Shared decision making, including a discussion of the long-term health benefits of salpingectomy, is important for couples deciding on permanent contraception procedures.</p>","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":" ","pages":"911-917"},"PeriodicalIF":4.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1097/AOG.0000000000006111
{"title":"PUBLICATIONS: December 2025.","authors":"","doi":"10.1097/AOG.0000000000006111","DOIUrl":"https://doi.org/10.1097/AOG.0000000000006111","url":null,"abstract":"","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"146 6","pages":"929"},"PeriodicalIF":4.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145655007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：